论文部分内容阅读
目的探索运用布拉酵母菌对儿童抗生素相关性腹泻(AAD)进行预防的临床效果。方法将我院2013年2月-2014年3月期间收治的240例非胃肠道感染患儿作为主要研究对象,随机将其分为对照组和观察组。其中将对照组的患儿进行对症支持和抗生素治疗;而观察组患儿在常规治疗和抗生素治疗的基础上,再运用布拉酵母菌进行综合治疗。对两组患儿的AAD发病率、腹泻总疗程以腹泻的大便次数等进行对比分析。结果经过不同治疗后,观察组有4例患儿发生AAD(3.33%),对照组有11例患儿发生AAD(9.17%),两组间相比较,差异有统计学意义(t=2.91,P<0.05);服药第4天治疗组患儿大便次数为(3.01±0.72),对照组为(3.84±1.34)次,两组间相比较差异有统计学意义(P<0.05);腹泻持续时间,观察组为(2.7±1.3)d,对照组为(4.1±2.1)d,两组间相比较差异有统计学意义(P<0.05)。结论运用布拉酵母菌预防AAD不仅可以缩短止泻时间和腹泻总疗程,在一定程度上还能有效降低AAD的发病率,值得在临床上被广泛地推广和应用。
Objective To explore the clinical efficacy of Saccharomyces boulardii in the prevention of childhood antibiotic-associated diarrhea (AAD). Methods A total of 240 children with non-gastrointestinal tract infections admitted to our hospital from February 2013 to March 2014 were selected as the main study subjects and randomly divided into control group and observation group. Among them, the control group of children with symptomatic support and antibiotic treatment; the observation group of children in the conventional treatment and antibiotic treatment, based on the use of Saccharomyces cerebrum comprehensive treatment. The incidence of AAD in both groups was compared with the total diarrhea stool frequency. Results After different treatments, AAD (3.33%) occurred in 4 cases in observation group and AAD (9.17%) in 11 cases in control group, the difference was statistically significant (t = 2.91, (3.01 ± 0.72) in the treatment group and (3.84 ± 1.34) in the control group, the difference was statistically significant (P <0.05) between the two groups; the duration of diarrhea (2.7 ± 1.3) days in the observation group and (4.1 ± 2.1) days in the control group. The difference between the two groups was statistically significant (P <0.05). Conclusion The prevention of AAD by Saccharomyces boulardii not only shortens the duration of antidiarrheal and the total course of diarrhea, but also reduces the incidence of AAD to a certain extent. It is worth to be widely popularized and applied clinically.